{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:56:06Z","timestamp":1791348966105,"version":"4.3.1"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>\n                    Systemic hypertension is one of the most common noncommunicable diseases globally, with over one billion people affected. Despite the widespread use of numerous antihypertensive drugs, it is estimated that only a fifth of diagnosed patients achieve adequate blood pressure control. For this reason, the pursuit for novel antihypertensive therapies is ongoing. Zilebesiran, an siRNA designed to target the liver, is the newest potential addition to the renin-angiotensin-aldosterone system-inhibiting drugs. This subcutaneous injection post-transcriptionally silences the\n                    <jats:italic toggle=\"yes\">AGT<\/jats:italic>\n                    gene responsible for the synthesis of angiotensinogen. By preventing the progenitor protein of the renin-angiotensin-aldosterone system, zilebesiran blocks the downstream production of angiotensin II, which plays multiple roles in blood pressure elevation. Phase I clinical trials have demonstrated a dose-dependent negative relationship between zilebesiran and blood pressure\/serum angiotensinogen levels\u2014with sustained effects up to 6 months. Researchers also demonstrated a promising safety profile, as most of the adverse events were mild to moderate in nature. Phase II trials assessing efficacy and optimal dosing are currently underway, with a predicted completion by 2025.\n                  <\/jats:p>","DOI":"10.1097\/crd.0000000000000645","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T09:03:17Z","timestamp":1708592597000},"page":"279-284","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Zilebesiran: A Promising Antihypertensive Therapy Inhibiting Angiotensinogen Synthesis"],"prefix":"10.1097","volume":"33","author":[{"given":"Rida S.","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"R3-20250404","doi-asserted-by":"crossref","first-page":"18014","DOI":"10.1038\/nrdp.2018.14","article-title":"Hypertension.","volume":"4","author":"Oparil","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"R4-20250404","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3390\/ijms17070797","article-title":"Role of the renin-angiotensin-aldosterone system beyond blood pressure regulation: molecular and cellular mechanisms involved in end-organ damage during arterial hypertension.","volume":"17","author":"Mu\u00f1oz-Durango","year":"2016","journal-title":"Int J Mol Sci"},{"key":"R5-20250404","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nrendo.2015.6","article-title":"Novel RAAS agonists and antagonists: clinical applications and controversies.","volume":"11","author":"Romero","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"R6-20250404","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11886-020-01352-8","article-title":"Should angiotensin-converting enzyme inhibitors ever be used for the management of hypertension?","volume":"22","author":"Turner","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"R7-20250404","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJMe2303534","article-title":"Silencing angiotensinogen in hypertension.","volume":"389","author":"Touyz","year":"2023","journal-title":"N Engl J Med"},{"key":"R8-20250404","first-page":"78","article-title":"siRNA: mechanism of action, challenges, and therapeutic approaches.","volume":"202","author":"Alshaer","year":"1741","journal-title":"Eur J Pharmacol"},{"key":"R10-20250404","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/hr.2013.155","article-title":"Targeting of hepatic angiotensinogen using chemically modified siRNAs results in significant and sustained blood pressure lowering in a rat model of hypertension.","volume":"37","author":"Olearczyk","year":"2014","journal-title":"Hypertension research: official journal of the Japanese Society of Hypertension"},{"key":"R11-20250404","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1161\/HYPERTENSIONAHA.119.12703","article-title":"Strong and sustained antihypertensive effect of small interfering RNA targeting liver angiotensinogen.","volume":"73","author":"Uijl","year":"2019","journal-title":"Hypertension"},{"key":"R12-20250404","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2208391","article-title":"Zilebesiran, an RNA interference therapeutic agent for hypertension.","volume":"389","author":"Desai","year":"2023","journal-title":"N Engl J Med"},{"key":"R15-20250404","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13054-015-0802-3","article-title":"Angiotensin II in septic shock.","volume":"19","author":"Corr\u00eaa","year":"2015","journal-title":"Crit Care"},{"key":"R16-20250404","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nbt.4136","article-title":"Reversal of siRNA-mediated gene silencing in vivo.","volume":"36","author":"Zlatev","year":"2018","journal-title":"Nat Biotechnol"},{"key":"R17-20250404","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1016\/j.amepre.2017.07.014","article-title":"Hypertensive Adults [published correction appears in Am J Prev Med 2020 Jun;58:898].","volume":"53","author":"Park","year":"2017","journal-title":"Am J Prev Med"},{"key":"R18-20250404","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1751-7176.2010.00397.x","article-title":"Combination therapy in hypertension.","volume":"13","author":"Gradman","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R19-20250404","first-page":"29","article-title":"Heart disease and stroke statistics \u2013 2015 Update.","volume":"131","author":"Mozaffarian","year":"2014","journal-title":"Circulation"},{"key":"R20-20250404","doi-asserted-by":"crossref","first-page":"e027694","DOI":"10.1161\/JAHA.122.027694","article-title":"Small Interfering RNA Therapeutics in Hypertension: a viewpoint on vasopressor and vasopressor-sparing strategies for counteracting blood pressure lowering by angiotensinogen\u2013targeting small interfering RNA.","volume":"11","author":"Ranasinghe","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"R21-20250404","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4103\/2249-4863.154630","article-title":"Resistant hypertension: an approach to management in primary care.","volume":"4","author":"Yaxley","year":"2015","journal-title":"J Family Med Prim Care"},{"key":"R22-20250404","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.5114\/aoms.2017.68650","article-title":"Lifestyle measures for treating hypertension.","volume":"13","author":"Aronow","year":"2017","journal-title":"Arch Med Sci"},{"key":"R28-20250404","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association.","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"R29-20250404","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","article-title":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.","volume":"400","author":"Schlaich","year":"2022","journal-title":"Lancet (London, England)"},{"key":"R30-20250404","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension.","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"R31-20250404","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41573-023-00670-0","article-title":"Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems.","volume":"22","author":"Baryakova","year":"2023","journal-title":"Nat Rev Drug Discov"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000000645","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:56:39Z","timestamp":1786035399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000000645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000645","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]}}}